Work

Supplementary Figure 13 from Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion

Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure 13. The levels of CTA, TAA, and tumor mutation burdens in different cohorts of transitional cell carcinoma patients treated with immune checkpoint inhibitors divided by tertiles of the CD8 T cell S3 scores. (a) The levels of CTA, TAA, and tumor mutation burdens in different patient groups of the IMVigor210 cohort divided by tertiles of the CD8 T cell S3 scores. The PD-L1 immune cell levels are illustrated as colored dots. R, responder (CR/PR), NR, non-responder (PD/SD). (b) The levels of CTA, TAA, and tumor mutation burdens in different groups of transitional cell carcinoma patients treated at UNC (Rose et al) divided by tertiles of the CD8 T cell S3 scores. PD-L1 TC or IC levels are not available in this dataset.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W7165008734
Cites:
Cited by:
Related to: 10